



(12) Translation of
European patent specification

(11) NO/EP 2850085 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 491/052 (2006.01)
A61K 31/4188 (2006.01)
A61P 31/12 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.08.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.03.15
(86)	European Application Nr.	13726936.1
(86)	European Filing Date	2013.05.15
(87)	The European Application's Publication Date	2015.03.25
(30)	Priority	2012.05.16, US, 201261647966 P 2013.03.14, US, 201313831116
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Gilead Pharmasset LLC, 333 Lakeside Drive, Foster City, CA 94404, US-USA
(72)	Inventor	LINK, John O., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, California 9440, US-USA COTTELL, Jeromy J., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, California 94404, US-USA TREJO MARTIN, Teresa Alejandra, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, California 94404, US-USA BACON, Elizabeth M., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, California 94404, US-USA
(74)	Agent or Attorney	Tandberg Innovation AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **ANTIVIRAL COMPOUNDS INHIBITORS OF HCV NS5A**


(56) References
Cited: WO-A1-2010/096777
WO-A2-2012/068234
XIAOFAN ZHENG ET AL: "Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 21, no. 10, 17 March 2011 (2011-03-17), pages 2925-2929, XP028199550, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2011.03.067 [retrieved on 2011-03-23]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav


1. En forbindelse med formel:

5



eller et farmasøytisk akseptabelt salt derav.

10 **2.** En forbindelse med formel:



15 **3.** Forbindelsen eller farmasøytisk akseptabelt salt ifølge krav 1, for anvendelse ved profylaktisk eller terapeutisk behandling av hepatitt C.

4. Et farmasøytisk preparat omfattende forbindelsen eller farmasøytisk akseptabelt salt ifølge krav 1, og minst én farmasøytisk akseptabel bærer.

20

5. Det farmasøytiske preparatet ifølge krav 4, formulert for oral administrering.

6. Det farmasøytiske preparatet ifølge krav 4, utformet i tablettform.

25 **7.** Det farmasøytiske preparatet ifølge krav 4, for anvendelse ved profylaktisk eller terapeutisk behandling av hepatitt C.